I've been picking up a few SBN over the last week or so following the drop to the low 2's.
The posts from the SBN regulars are confirming that drug testing is a great market to be in, and SBN's market penetration is increasing.
I'm interested in other's thoughts as to a possible takeover of SBN. It's generally agreed that SBN has some cashflow issues coming up, and their market cap is tiny. Their greatest limiting factor at present seems to be finance.
With Oraline's greater sensitivity yet to be duplicated by their competitors, how attractive is the IP?
Which also raises the obvious questions - how protected is the IP?
Add to My Watchlist
What is My Watchlist?